Abstract
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have